Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

8.015 +0.185 (+2.36%)
Streaming Delayed Price Updated: 10:06 AM EDT, Sep 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arvinas, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach
Via Stocktwits
Arvinas Inc (NASDAQ:ARVN) Reports Q2 2025 Earnings: Revenue Misses but EPS Beats Estimates
Arvinas Q2 2025 earnings: Revenue missed estimates at $22.4M, but EPS beat at -$0.84. NDA submitted for vepdegestrant, ARV-102 advances in trials. Shares fell pre-market. 
Via Chartmill
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
 
Via Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
 
Via Benzinga
Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval
Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- breast cancer patients 
Via Benzinga
What Analysts Are Saying About Arvinas Stock
 
Via Benzinga
Earnings Scheduled For May 1, 2025
 
Via Benzinga
SAIC, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Where Arvinas Stands With Analysts
 
Via Benzinga
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
Here are the top movers in Thursday's session.
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Top stock movements in today's session.
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Dow Surges Over 300 Points; McDonald's Posts Weak Revenue
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
The market is filled with gapping stocks in Thursday's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday. 
Via Chartmill
Nasdaq Jumps 1.5%; Microsoft Posts Upbeat Results
 
Via Benzinga
These stocks are moving in today's pre-market session
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
A Peek at Arvinas's Future Earnings
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study
Arvinas' ARV-102 reduced LRRK2 protein in a Phase 1 trial, showing promising safety and pharmacodynamic outcomes for Parkinson's and PSP treatment. 
Via Benzinga
Top 3 Health Care Stocks That Are Set To Fly This Month
 
Via Benzinga
Tesla To $120? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
 
Via Benzinga
Tuesday's session: top gainers and losers
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients. 
Via Benzinga
Gapping stocks in Tuesday's session
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
Crude Oil Gains 1%; Ciena Earnings Top Views
 
Via Benzinga
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug
The companies are looking to use protein degradation to take on some forms of breast cancer. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.